Combined treatment of pegvisomant and cabergoline in a cat with hypersomatotropism: insulin-like growth factor 1 normalization and control of comorbidities

Autores
Miceli, Diego Daniel; Rey Amunategui, Juan P.; Pompili, Gustavo A.; Más, Javier; Pignataro, Omar Pedro; Guitelman, Mirtha
Año de publicación
2026
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Case summary A 19-year-old, spayed female domestic shorthair cat was referred with diabetes mellitus and difficulties in achieving glycemic control. Hypersomatotropism (HST) was diagnosed based on clinical signs compatible with acromegaly (prognathia inferior, broad facial features and abdominal enlargement), increased serum insulin-like growth factor 1 (IGF-1) concentration (4430 ng/ml) and pituitary enlargement (height 4.7 mm). Serum IGF-1 concentrations, biochemical analysis and urinalysis were performed at the time of HST diagnosis and after 10, 20, 30, 60, 120 and 180 days of pegvisomant treatment (PEGV, Somarvet; Pfizer). The cat received PEGV (1 mg/kg SC q24h) in combination with cabergoline (10 μg/kg PO q48h). Serum IGF-1 concentrations decreased abruptly to 396 ng/ml on day 10 of PEGV treatment and blood glucose concentrations also decreased rapidly. Insulin was no longer required after 7 days of PEGV. From day 30 (IGF-1 286 ng/ml), PEGV was administered q48h and the same therapeutic response was maintained after60 days of treatment (IGF-1 290 ng/ml and diabetic remission). From day 120, PEGV was administered once weekly and normal IGF-1 concentrations (270 ng/ml) were observed after 180 days of treatment. The cat also showed improvements in echocardiographic variables and in her quality of life (QoL) score.Relevance and novel information This is the first reported case of PEGV plus cabergoline treatment in a cat with HST. The results suggest that the combined treatment of PEGV and cabergoline was associated with normalization of IGF-1 concentrations, diabetic remission, and improvement of cardiovascular function and QoL over a short period.
Fil: Miceli, Diego Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Rey Amunategui, Juan P.. Universidad de Buenos Aires. Facultad de Ciencias Veterinarias; Argentina
Fil: Pompili, Gustavo A.. Universidad de Buenos Aires. Facultad de Ciencias Veterinarias; Argentina
Fil: Más, Javier. No especifíca;
Fil: Pignataro, Omar Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Guitelman, Mirtha. Gobierno de la Ciudad Autonoma de Buenos Aires. Hospital General de Agudos Carlos Durand.; Argentina
Materia
PEGVISOMANT
GH EXCESS
DIABETIC REMISSION
ACROMEGALY
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/286944
Acceder
id CONICETDig_beb5d29ee0325c8f45b6b3412a3c86dc
oai_identifier_str oai:ri.conicet.gov.ar:11336/286944
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Combined treatment of pegvisomant and cabergoline in a cat with hypersomatotropism: insulin-like growth factor 1 normalization and control of comorbiditiesMiceli, Diego DanielRey Amunategui, Juan P.Pompili, Gustavo A.Más, JavierPignataro, Omar PedroGuitelman, MirthaPEGVISOMANTGH EXCESSDIABETIC REMISSIONACROMEGALYhttps://purl.org/becyt/ford/4.3https://purl.org/becyt/ford/4Case summary A 19-year-old, spayed female domestic shorthair cat was referred with diabetes mellitus and difficulties in achieving glycemic control. Hypersomatotropism (HST) was diagnosed based on clinical signs compatible with acromegaly (prognathia inferior, broad facial features and abdominal enlargement), increased serum insulin-like growth factor 1 (IGF-1) concentration (4430 ng/ml) and pituitary enlargement (height 4.7 mm). Serum IGF-1 concentrations, biochemical analysis and urinalysis were performed at the time of HST diagnosis and after 10, 20, 30, 60, 120 and 180 days of pegvisomant treatment (PEGV, Somarvet; Pfizer). The cat received PEGV (1 mg/kg SC q24h) in combination with cabergoline (10 μg/kg PO q48h). Serum IGF-1 concentrations decreased abruptly to 396 ng/ml on day 10 of PEGV treatment and blood glucose concentrations also decreased rapidly. Insulin was no longer required after 7 days of PEGV. From day 30 (IGF-1 286 ng/ml), PEGV was administered q48h and the same therapeutic response was maintained after60 days of treatment (IGF-1 290 ng/ml and diabetic remission). From day 120, PEGV was administered once weekly and normal IGF-1 concentrations (270 ng/ml) were observed after 180 days of treatment. The cat also showed improvements in echocardiographic variables and in her quality of life (QoL) score.Relevance and novel information This is the first reported case of PEGV plus cabergoline treatment in a cat with HST. The results suggest that the combined treatment of PEGV and cabergoline was associated with normalization of IGF-1 concentrations, diabetic remission, and improvement of cardiovascular function and QoL over a short period.Fil: Miceli, Diego Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Rey Amunategui, Juan P.. Universidad de Buenos Aires. Facultad de Ciencias Veterinarias; ArgentinaFil: Pompili, Gustavo A.. Universidad de Buenos Aires. Facultad de Ciencias Veterinarias; ArgentinaFil: Más, Javier. No especifíca;Fil: Pignataro, Omar Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Guitelman, Mirtha. Gobierno de la Ciudad Autonoma de Buenos Aires. Hospital General de Agudos Carlos Durand.; ArgentinaSAGE Publications2026-02info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/286944Miceli, Diego Daniel; Rey Amunategui, Juan P.; Pompili, Gustavo A.; Más, Javier; Pignataro, Omar Pedro; et al.; Combined treatment of pegvisomant and cabergoline in a cat with hypersomatotropism: insulin-like growth factor 1 normalization and control of comorbidities; SAGE Publications; Journal of Feline Medicine and Surgery Open Reports; 12; 1; 2-2026; 1-72055-11692055-1169CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://journals.sagepub.com/doi/10.1177/20551169261427069info:eu-repo/semantics/altIdentifier/doi/10.1177/20551169261427069info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2026-06-17T09:40:37Zoai:ri.conicet.gov.ar:11336/286944instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982026-06-17 09:40:37.549CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Combined treatment of pegvisomant and cabergoline in a cat with hypersomatotropism: insulin-like growth factor 1 normalization and control of comorbidities
title Combined treatment of pegvisomant and cabergoline in a cat with hypersomatotropism: insulin-like growth factor 1 normalization and control of comorbidities
spellingShingle Combined treatment of pegvisomant and cabergoline in a cat with hypersomatotropism: insulin-like growth factor 1 normalization and control of comorbidities
Miceli, Diego Daniel
PEGVISOMANT
GH EXCESS
DIABETIC REMISSION
ACROMEGALY
title_short Combined treatment of pegvisomant and cabergoline in a cat with hypersomatotropism: insulin-like growth factor 1 normalization and control of comorbidities
title_full Combined treatment of pegvisomant and cabergoline in a cat with hypersomatotropism: insulin-like growth factor 1 normalization and control of comorbidities
title_fullStr Combined treatment of pegvisomant and cabergoline in a cat with hypersomatotropism: insulin-like growth factor 1 normalization and control of comorbidities
title_full_unstemmed Combined treatment of pegvisomant and cabergoline in a cat with hypersomatotropism: insulin-like growth factor 1 normalization and control of comorbidities
title_sort Combined treatment of pegvisomant and cabergoline in a cat with hypersomatotropism: insulin-like growth factor 1 normalization and control of comorbidities
dc.creator.none.fl_str_mv Miceli, Diego Daniel
Rey Amunategui, Juan P.
Pompili, Gustavo A.
Más, Javier
Pignataro, Omar Pedro
Guitelman, Mirtha
author Miceli, Diego Daniel
author_facet Miceli, Diego Daniel
Rey Amunategui, Juan P.
Pompili, Gustavo A.
Más, Javier
Pignataro, Omar Pedro
Guitelman, Mirtha
author_role author
author2 Rey Amunategui, Juan P.
Pompili, Gustavo A.
Más, Javier
Pignataro, Omar Pedro
Guitelman, Mirtha
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv PEGVISOMANT
GH EXCESS
DIABETIC REMISSION
ACROMEGALY
topic PEGVISOMANT
GH EXCESS
DIABETIC REMISSION
ACROMEGALY
purl_subject.fl_str_mv https://purl.org/becyt/ford/4.3
https://purl.org/becyt/ford/4
dc.description.none.fl_txt_mv Case summary A 19-year-old, spayed female domestic shorthair cat was referred with diabetes mellitus and difficulties in achieving glycemic control. Hypersomatotropism (HST) was diagnosed based on clinical signs compatible with acromegaly (prognathia inferior, broad facial features and abdominal enlargement), increased serum insulin-like growth factor 1 (IGF-1) concentration (4430 ng/ml) and pituitary enlargement (height 4.7 mm). Serum IGF-1 concentrations, biochemical analysis and urinalysis were performed at the time of HST diagnosis and after 10, 20, 30, 60, 120 and 180 days of pegvisomant treatment (PEGV, Somarvet; Pfizer). The cat received PEGV (1 mg/kg SC q24h) in combination with cabergoline (10 μg/kg PO q48h). Serum IGF-1 concentrations decreased abruptly to 396 ng/ml on day 10 of PEGV treatment and blood glucose concentrations also decreased rapidly. Insulin was no longer required after 7 days of PEGV. From day 30 (IGF-1 286 ng/ml), PEGV was administered q48h and the same therapeutic response was maintained after60 days of treatment (IGF-1 290 ng/ml and diabetic remission). From day 120, PEGV was administered once weekly and normal IGF-1 concentrations (270 ng/ml) were observed after 180 days of treatment. The cat also showed improvements in echocardiographic variables and in her quality of life (QoL) score.Relevance and novel information This is the first reported case of PEGV plus cabergoline treatment in a cat with HST. The results suggest that the combined treatment of PEGV and cabergoline was associated with normalization of IGF-1 concentrations, diabetic remission, and improvement of cardiovascular function and QoL over a short period.
Fil: Miceli, Diego Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Rey Amunategui, Juan P.. Universidad de Buenos Aires. Facultad de Ciencias Veterinarias; Argentina
Fil: Pompili, Gustavo A.. Universidad de Buenos Aires. Facultad de Ciencias Veterinarias; Argentina
Fil: Más, Javier. No especifíca;
Fil: Pignataro, Omar Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Guitelman, Mirtha. Gobierno de la Ciudad Autonoma de Buenos Aires. Hospital General de Agudos Carlos Durand.; Argentina
description Case summary A 19-year-old, spayed female domestic shorthair cat was referred with diabetes mellitus and difficulties in achieving glycemic control. Hypersomatotropism (HST) was diagnosed based on clinical signs compatible with acromegaly (prognathia inferior, broad facial features and abdominal enlargement), increased serum insulin-like growth factor 1 (IGF-1) concentration (4430 ng/ml) and pituitary enlargement (height 4.7 mm). Serum IGF-1 concentrations, biochemical analysis and urinalysis were performed at the time of HST diagnosis and after 10, 20, 30, 60, 120 and 180 days of pegvisomant treatment (PEGV, Somarvet; Pfizer). The cat received PEGV (1 mg/kg SC q24h) in combination with cabergoline (10 μg/kg PO q48h). Serum IGF-1 concentrations decreased abruptly to 396 ng/ml on day 10 of PEGV treatment and blood glucose concentrations also decreased rapidly. Insulin was no longer required after 7 days of PEGV. From day 30 (IGF-1 286 ng/ml), PEGV was administered q48h and the same therapeutic response was maintained after60 days of treatment (IGF-1 290 ng/ml and diabetic remission). From day 120, PEGV was administered once weekly and normal IGF-1 concentrations (270 ng/ml) were observed after 180 days of treatment. The cat also showed improvements in echocardiographic variables and in her quality of life (QoL) score.Relevance and novel information This is the first reported case of PEGV plus cabergoline treatment in a cat with HST. The results suggest that the combined treatment of PEGV and cabergoline was associated with normalization of IGF-1 concentrations, diabetic remission, and improvement of cardiovascular function and QoL over a short period.
publishDate 2026
dc.date.none.fl_str_mv 2026-02
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/286944
Miceli, Diego Daniel; Rey Amunategui, Juan P.; Pompili, Gustavo A.; Más, Javier; Pignataro, Omar Pedro; et al.; Combined treatment of pegvisomant and cabergoline in a cat with hypersomatotropism: insulin-like growth factor 1 normalization and control of comorbidities; SAGE Publications; Journal of Feline Medicine and Surgery Open Reports; 12; 1; 2-2026; 1-7
2055-1169
2055-1169
CONICET Digital
CONICET
url http://hdl.handle.net/11336/286944
identifier_str_mv Miceli, Diego Daniel; Rey Amunategui, Juan P.; Pompili, Gustavo A.; Más, Javier; Pignataro, Omar Pedro; et al.; Combined treatment of pegvisomant and cabergoline in a cat with hypersomatotropism: insulin-like growth factor 1 normalization and control of comorbidities; SAGE Publications; Journal of Feline Medicine and Surgery Open Reports; 12; 1; 2-2026; 1-7
2055-1169
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://journals.sagepub.com/doi/10.1177/20551169261427069
info:eu-repo/semantics/altIdentifier/doi/10.1177/20551169261427069
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv SAGE Publications
publisher.none.fl_str_mv SAGE Publications
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1868338992462692352
score 13.040872

Publicaciones similares